Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00276757|
Recruitment Status : Completed
First Posted : January 13, 2006
Last Update Posted : January 10, 2014
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may be an effective treatment for Langerhans cell histiocytosis.
PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well it works in treating young patients with Langerhans cell histiocytosis.
|Condition or disease||Intervention/treatment||Phase|
|Childhood Langerhans Cell Histiocytosis||Drug: leucovorin calcium Drug: methotrexate Drug: prednisolone Drug: vinblastine sulfate||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||376 participants|
|Official Title:||Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis|
|Study Start Date :||April 2001|
|Actual Study Completion Date :||June 2013|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276757
|Study Chair:||Kenneth L. McClain, MD, PhD||Texas Children's Cancer Center|